Judith F. Margolin, MD
Co-Director, Pediatric Hematology-Oncology Vascular Anomalies Program, Associate Professor, Department of Pediatrics, Section of Hematology-Oncology, Baylor College of Medicine
Office locations:
Texas Medical Center
6701 Fannin Street
Houston, TX 77030
Get to know Judith F. Margolin, MD
Dr. Judith Margolin is Co-Director of the Pediatric Hematology-Oncology Vascular Anomalies Program at Texas Children's Hospital. Her clinical interests include: leukemia, lymphoma, vascular anomalies, and hematologic disorders. She is board certified by the American Board of Pediatrics in general pediatrics and pediatric hematology-oncology.
Education
| School | Education | Degree | Year |
|---|---|---|---|
| University of Pennsylvania Health System | Fellowship | Pediatric Hematology Oncology | 1991 |
| Baylor College of Medicine | Residency | Pediatrics | 1988 |
| Baylor College of Medicine | Internship | Pediatrics | 1986 |
| University of Cincinnati College of Medicine | Medical School | Doctor of Medicine | 1985 |
Honors and awards
Master Clinician Award for Excellence in Patient Care, Baylor College of Medicine
* Texas Children’s Hospital physicians’ licenses and credentials are reviewed prior to practicing at any of our facilities. Sections titled From the Doctor, Professional Organizations and Publications were provided by the physician’s office and were not verified by Texas Children’s Hospital.
Research Area:
Leukemia
Lymphoma
Dr. Judy Margolin is interested in the patterns of gene expression, which occur in normal hemopoietic cells during development, differentiation, and immune response. Her laboratory also studies gene expression patterning in leukemic blast cells, hepatoblastoma cells, and other pediatric cancers. The role of transcription factors in controlling gene expression patterns, as well as the patterns themselves, is the subject of investigation.
Current projects in the lab include: identifying specific transcription factors that are expressed in these systems, investigating the transcriptional activities of known oncogenes and tumor suppressor genes, construction of cDNA library for sequencing and hybridization experiments, and the use of some of the key components of the expression patterns as therapeutic or immunologic targets for future therapies.
